The clinical application of intravitreal injection (IVI) with anti-VEGF agents has recently increased due to their fewer side effects and more advantages, including a lower risk of future myopia, better peripheral vision, and faster regression of acute-phase ROP [7-10]. This evidence concerns the gene VEGFA and retinopathy of prematurity.